Evaluating immune response in malignant gliomas using MRI and immunophenotyping
Identification of the Immuno Suppressive Characteristics of Glioma Patients by an Integrated Radio-immunological Approach
This study is trying to see how the immune system responds in patients with aggressive brain tumors called glioblastomas by using advanced imaging and testing the tumor's environment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Istituto Oncologico Veneto IRCCS Academic / other |
| Locations | 2 sites (Florence and 1 other locations) |
| Trial ID | NCT05267509 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with malignant gliomas, particularly glioblastomas, which are known for their aggressive nature and immune suppression. The research aims to assess the infiltration of myeloid cells and the metabolism of iron in tumor-associated macrophages by utilizing a combination of advanced MRI imaging techniques and immunophenotyping of the tumor microenvironment. By understanding these immune dynamics, the study seeks to provide insights into the tumor's behavior and potential therapeutic targets.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with histologically confirmed malignant glioma who can undergo MRI scans with gadolinium contrast.
Not a fit: Patients with non-malignant brain tumors or those unable to undergo MRI scans may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of glioblastoma biology and lead to improved treatment strategies for patients.
How similar studies have performed: While the approach of combining MRI with immunophenotyping is innovative, similar studies have shown promise in understanding tumor microenvironments in other cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients with histologic confirmation of malignant glioma * Patients must be age \>= 18 years * Patients must be able to obtain an MRI scan with gadolinium contrast * Patients must sign informed consent indicating that they are aware of the investigational nature of this study:
Where this trial is running
Florence and 1 other locations
- University Hospital — Florence, Italy (Recruiting)
- University Hospital — Padova, Italy (Recruiting)
Study contacts
- Principal investigator: Susanna Mandruzzato, PhD — Istituto Oncologico Veneto IOV-IRCCS
- Study coordinator: Susanna Mandruzzato, PhD
- Email: susanna.mandruzzato@unipd.it
- Phone: +39 049 8215898
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.